Is Medvi Legit? What Its BBB File, Trustpilot Reviews, and FDA Letter Actually Show

Two very different stories about Medvi were both being told in the same season. In April 2026, the New York Times profiled it as a proof-of-concept for a one-person, AI-run, billion-dollar company. Within days, Futurism and other outlets were pointing out that Medvi's ads had featured deepfaked before-and-after photos and AI-generated doctors with names like "Professor Albust Dongledore," and that the FDA had already sent the company a warning letter two months earlier. Both threads are true at once, and neither one by itself tells you whether it's safe to hand Medvi your health history and your card number. Here's what the primary records actually show, checked fresh as of this writing.

Is Medvi legit, or is it a scam?

Legit, in the sense that matters most: Medvi runs a real medical intake, routes prescriptions through licensed clinicians, and fills them at a named, licensed compounding pharmacy. It is not a storefront that takes a payment and disappears — the medication ships, and the large majority of reviewers describe it arriving and working as expected. That puts it in a different category from an outright scam.

It's also a company with a genuinely rougher trust record than most brands we audit this way. It holds an F rating with the Better Business Bureau, it's carrying an FDA warning letter that, as of this writing, shows no public sign of being resolved, and independent reporting has documented AI-generated fake doctors and deepfaked patient photos in its own advertising — not just an anonymous marketing vendor's overreach, but content that ran under Medvi's name. None of that means the medicine itself is fake or unsafe. It does mean Medvi's own marketing has repeatedly said things that weren't true, which is a different and more specific problem than the billing friction that shows up on most telehealth BBB files.

Who actually runs Medvi — the company behind the ads

Medvi is built and run by founder Matthew Gallagher and his brother Elliot — by most reporting, a two-person core team that reportedly started the business with about $20,000 and no outside investment. That's the detail behind the New York Times' April 2, 2026 profile, which reported $401 million in 2025 sales and a projected $1.8 billion in 2026 revenue as evidence that a tiny team using AI tools could run a company at that scale. Worth being precise about that number: it's a revenue run-rate, a projection built by annualizing early-2026 sales, not a company valuation — Medvi hasn't raised outside funding and has no independent valuation, which several outlets pushed back on within days of the profile running.

That pushback is the more useful half of the story for a shopper. Futurism and Techdirt both argued the Times profile missed or downplayed a parallel record: fabricated marketing content, an active FDA warning letter, and litigation, all predating the profile. Reasonable people can debate whether a two-person team running a nine-figure telehealth business is impressive, concerning, or both — the practical point is that Medvi's public-facing story is genuinely split down the middle between an efficiency narrative and an accountability one, and it's worth reading past whichever headline you saw first.

Does a real doctor review your case before you're prescribed anything?

Yes, and this is the part that's easy to lose in the AI-marketing headlines. Medvi doesn't practice medicine directly — prescribing runs through OpenLoop Health, a physician-staffing network that also backs several other GLP-1 telehealth brands, with intake and compliance handled by a separate vendor, CareValidate. The clinicians who review your questionnaire and write your prescription are real, licensed providers working through that network, not an AI system and not the fabricated "doctors" that showed up in Medvi's ads.

That's exactly the distinction that got blurred and is worth drawing clearly. The fake doctors Futurism identified — AI-generated video testimonials attached to invented names, plus at least one real physician's name and photo used without his knowledge or consent — appeared in Medvi's marketing and affiliate advertising, not in the actual clinical intake. Medvi's site also displays a LegitScript certification seal, a real third-party compliance check on telehealth and pharmacy operators; LegitScript, not Medvi, is the authority on whether that status is still current, so it's worth confirming directly on LegitScript's own certification lookup rather than taking the badge at face value. The honest takeaway: the person reviewing your intake is very likely a real, licensed clinician — the company's ad copy about doctors is a separate, considerably less trustworthy channel, and the two shouldn't be confused with each other.

What does Medvi's BBB file actually show?

As of September 18, 2026, Medvi's BBB profile shows an F letter rating, no BBB accreditation, and 736 complaints filed. That's up from 726 complaints when this figure was last checked for Medvi's main review on September 9, 2026 — a reminder that this file moves by the day, and any number quoted here, including this one, is a snapshot rather than a fixed fact. BBB attributes the F grade to the complaint volume and the company's pattern of unresolved responses rather than to a single incident.

The complaints skew toward process, not product: no cancel button on the site, email and portal chat that don't process cancellations, calls routed through multiple retention agents before reaching anyone who can actually cancel a subscription, and a refund window some reviewers describe as effectively closed after 72 hours. One more wrinkle worth knowing before you search this yourself: a similarly named but unrelated mental-health company, MEDvidi, shows up in some searches and aggregator write-ups and gets its complaints and Medvi's mixed together. Confirm you're looking at medvi.org's own BBB file, not MEDvidi's, before drawing conclusions from any third-party summary.

Trustpilot says one thing, BBB says another — how do you reconcile that?

Both numbers are real, and they're measuring different things. On Trustpilot, Medvi sits at 4.3 out of 5 across roughly 14,774 reviews as of this writing, with about 79% five-star and 12% one-star. That's a meaningfully larger review pool than the 11,000-plus figure recorded in early September, and the rating has slipped slightly, from 4.4 to 4.3, over that same short window — both worth re-checking directly if you're reading this more than a few weeks out, since a base this size can move fast.

Read together, the two platforms describe the same company from opposite ends of the experience. Trustpilot's large, mostly-positive sample reflects what happens for most subscribers: medication ships, providers respond, people report losing weight. BBB's smaller, entirely negative sample captures the minority who hit a real problem — usually billing or cancellation — and couldn't get it resolved through Medvi's own support channel, so they escalated. Twelve percent one-star on a base of nearly 15,000 reviews and 736 open BBB complaints aren't contradictory; they're two views of the same friction, seen at different scales.

What was the FDA warning letter about, and is it still open?

On February 20, 2026, the FDA sent MEDVi, LLC a warning letter — letter #721455 — citing misbranding under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. Two things drove the letter: website language stating its compounded products had the "same active ingredient as Wegovy® and Ozempic®" or "same active ingredient as Mounjaro® and Zepbound®," which the FDA said implied the compounded versions had been evaluated and approved the way the brand-name drugs were, and product labels bearing the Medvi name in a way that suggested Medvi itself compounded the medication — when the actual compounding is done by its pharmacy partner, not Medvi. Medvi wasn't singled out: the FDA sent similar letters to more than 30 telehealth companies the following month, in an industry-wide sweep over comparable marketing language.

What happened next is the part worth knowing before you treat this as settled. Medvi's founder initially told reporters the FDA-cited website, medvi.io, belonged to an affiliate marketing agency and that Medvi itself had "never received a letter" from the FDA — a claim that doesn't square with the letter itself, which was addressed directly to "MEDVi, LLC dba MEDVi" at the company's own registered email address. On April 9, 2026, the founder issued a public response that struck a different tone, acknowledging advertising problems and committing to prohibit AI-generated fake-doctor content going forward. As of this writing, seven months after the letter was issued, there's no public record of a follow-up FDA action, a resolution, or a formal close-out — which is normal; the FDA doesn't typically publish a letter's resolution status, and warning letters are described in the agency's own procedures as informal and advisory rather than a final enforcement action. Practically, that means the letter should be read as open and unresolved rather than settled, and it's worth checking FDA's enforcement page yourself for any update closer to when you're reading this.

Which pharmacy fills Medvi's prescriptions, and does that matter?

Medvi's compounded semaglutide and tirzepatide are prepared by Belmar Pharma Solutions, a compounding pharmacy operating since 1985 out of Golden, Colorado, working under 503A/503B rules. That's a real, licensable, checkable pharmacy — a materially different situation from a company that won't name who's actually making the medication.

It matters because Medvi itself doesn't compound anything, doesn't employ the prescribers, and doesn't own a pharmacy — it's the marketing and intake layer sitting on top of a stack of outside vendors: OpenLoop Health for clinicians, Belmar for the medication, CareValidate for backend compliance and fulfillment. That structure is common across compounded-GLP-1 telehealth, not unique to Medvi, but it means that if something goes wrong with a shipment or a bill, you may be dealing with whichever vendor in that chain actually owns the problem, not a single integrated clinic — worth knowing going in, separate from whether the pharmacy itself is legitimate.

Is Medvi safe for a woman in perimenopause specifically?

Medvi doesn't run a menopause or hormone-therapy track the way some competitors do — its catalog is compounded semaglutide and tirzepatide (tablet or injection) plus a broker path to brand-name Zepbound and Wegovy, and that's it. So the legitimacy question for a perimenopausal woman considering it is largely the same one anyone else would ask, with two things worth naming specifically. First, a compounded GLP-1's real safety depends on your intake being complete and honest — if you're on hormone therapy, thyroid medication, or anything else, that needs to reach the actual OpenLoop clinician reviewing your case, not get lost in an app flow. Second, given the documented history of AI-generated "doctor" content in Medvi's own ads, it's reasonable to want extra certainty that any follow-up message asking for more information or claiming to be your provider is coming from your actual assigned clinician rather than an automated or affiliate channel — a level of caution that shouldn't be necessary, but the record here makes it a fair one to apply.

For how GLP-1 medications and perimenopausal weight change actually relate — separate from any one company's marketing — see our guide to GLP-1 medications and menopause.

So — is Medvi legit? Our verdict

Yes, with real caveats that go beyond the usual telehealth billing complaints. Medvi is a genuine, operating business: real prescribers through an established clinician network, real compounded medication from a named, licensed pharmacy, and a large volume of Trustpilot reviewers reporting exactly the experience the ads promise. It is not the kind of operation that takes your money and vanishes.

Set against that: an F-rated BBB file with 736 open complaints, an FDA warning letter that shows no sign of resolution seven months in, and a documented pattern of fabricated doctors and deepfaked patient photos in Medvi's own advertising — a credibility problem that sits closer to the marketing itself than the billing friction most audited brands carry. Compare that to a company like Henry Meds, whose most serious open issue is a trademark dispute with Eli Lilly rather than an FDA misbranding letter, or Mochi Health, which leans on named, ABOM-certified prescribers as a selling point. None of that makes Medvi a scam. It makes it a company worth using with your eyes fully open: read the cancellation terms before you enroll, confirm your ongoing dose price in writing, and don't take anything in Medvi's own ad creative — including any doctor pictured in it — at face value. For the full pricing and plan breakdown, see the complete Medvi review and the Medvi cost guide; for how another young telehealth brand's legitimacy record reads by comparison, see is Gala GLP-1 legit.